SEARCH

SEARCH BY CITATION

References

  • 1
    Vaughan DE, Schafer AI, Loscalzo J. Normal mechanisms of haemostasis and fibrinolysis. In: Loscalzo J, Creager MMA, Dzau VJ, eds. Vascular Medicine. Boston, Toronto, London: Little, Brown and Company, 1992; 233 50.
  • 2
    Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan I et al Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111 15.
  • 3
    Liberman EH, Gerhard MD, Uehata et al Flow-induced vasodilatation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol 1996; 78: 1210 14.
  • 4
    Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopolous D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994; 24: 471 6.
  • 5
    Celermajer D, Sorensen K, Georgakopoulos D, Bull C, Thomas O, Robinson et al Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88: 2149 55.
  • 6
    Jensen-Urstad KJ, Reichard PG, Rosfors JS, Lindblad LEL, Jensen-Urstad MT. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM. Diabetes 1996; 45: 1253 8.
  • 7
    Vogel RA, Coretti MC, Plotnick GD. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am J Cardiol 1996; 77: 37 40.
  • 8
    Ross R. The pathogenesis of atherosclerosis – an update. N Engl J Med 1986; 314: 488 500.
  • 9
    Kadish J. Endothelium, fibrinolysis, cardiac risk factors, and prostaglandins: a unified model of atherogensis. Med Hypothesis 1995; 45: 295 313.
  • 10
    Lijnen HR & Collen D. Endothelium in haemostasis and thrombosis. Prog Cardiovasc Dis 1997; 39: 343 50.
  • 11
    Vogel RA. Coronary risk factors, endothelial function and atherosclerosis; a review. Clin Cardiol 1997; 20: 226 32.
  • 12
    Jensen-Urstad K, Johansson J, Jensen-Urstad M. Vascular function correlates with risk factors for cardiovascular disease in a healthy population of 35 year old subjects. J Intern Med 1997; 241: 507 13.
  • 13
    Anderson TGM, Meredith I, Charbonneau F, Delagrange D, Craeger M, Selwyn et alSystemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995; 75: 71B 4B.
  • 14
    Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange et al Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235 41.
  • 15
    Chmielewska J & Wiman B. Determination of tissue plaminogen activator and its ‘fast’ inhibitor in plasma. Clin Chim Acta 1986; 32: 482 5.
  • 16
    Tegner-Nilsson A-C, Friberger P, Gyzander E. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest 1977; 37: 403 9.
  • 17
    Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas et al Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995; 74: 247 53.
  • 18
    Wiman B & Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573 8.
  • 19
    Levi M, Roem D, Kamp AM, de Boer JP, Hack CE, ten Cate JW. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993; 69: 141 6.
  • 20
    Marongiu F, Mulas G, Mamusa AM, Mameli G, Marassi PP, Tronci M et al Relationship between elevated fibrinopeptide A levels and alpha2-antiplasmin. Haemostasis 1987; 17: 301 4.
  • 21
    Wilcox JN, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong C, Hayzer D et al Characterizaion of thrombin receptor expression during vascular lesion formation. Circ Res 1994; 75: 1029 38.
  • 22
    Robbie LA, Booth NA, Brown AJ, Bennet B. Inhibitors of fibrinolysis are elevated in atherosclerosis plaque. Arterioscler Thromb Vasc Biol 1996; 16: 539 45.
  • 23
    Sukata Y & Aoki N. Cross-linking of alpha2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290 7.
  • 24
    Sobel JH & Gawinowicz MA. Identification of the alpha chain lysine donor sites involved in factor XIIIa fibrin cross-linking. J Biol Chem 1996; 271: 19288 97.
  • 25
    Fair DS & Plow EF. Synthesis and secretion of the fibrinolytic components, including alpha2 antiplasmin, by a human hepatoma cell line. J Lab Clin Med 1983; 101: 372 84.
  • 26
    Knot EA, Drijfhout HR, ten Cate J et al Alpha2-Plasmin inhibitor metabolism in patients with liver cirrhosis. J Lab Clin Med 1985; 105: 353 8.